Laurel Venture Capital acquires Alpine's GSNOR assets
Laurel Venture Capital has acquired Alpine Immune Sciences' S-Nitrosoglutathione Reductase assets. No financial terms were disclosed. Seattle-based Alpine is focused on discovering and developing protein-based immunotherapies to treat cancer, autoimmune/inflammatory illnesses and other diseases.
20 July 2018•3 mins read
